CYTK – cytokinetics, incorporated (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

CYTK

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/22

05:36 pm

cytk

Cytokinetics: Small Label Differences With Big Commercial Stakes [Seeking Alpha]

Low Report

Cytokinetics: Small Label Differences With Big Commercial Stakes [Seeking Alpha]

Report

12/22

02:08 pm

cytk

Cytokinetics (NASDAQ:CYTK) was given a new $84.00 price target on by analysts at Truist Financial Corporation.

Low Report

Cytokinetics (NASDAQ:CYTK) was given a new $84.00 price target on by analysts at Truist Financial Corporation.

Report

12/22

01:07 pm

cytk

Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Medium Report

Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Report

12/22

01:07 pm

cytk

Cytokinetics (NASDAQ:CYTK) was given a new $83.00 price target on by analysts at Leerink Partners.

Medium Report

Cytokinetics (NASDAQ:CYTK) was given a new $83.00 price target on by analysts at Leerink Partners.

Report

12/22

09:49 am

cytk

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript [Seeking Alpha]

Medium Report

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript [Seeking Alpha]

Report

12/22

09:13 am

cytk

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Holley Inc. (NYSE: HLLY); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Low Report

Report

12/22

08:07 am

cytk

Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Low Report

Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

12/22

08:02 am

cytk

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Needham & Company LLC from $72.00 to $84.00. They now have a "buy" rating on the stock.

Low Report

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Needham & Company LLC from $72.00 to $84.00. They now have a "buy" rating on the stock.

Report

12/22

08:02 am

cytk

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Citizens Jmp from $78.00 to $88.00. They now have a "market outperform" rating on the stock.

Low Report

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Citizens Jmp from $78.00 to $88.00. They now have a "market outperform" rating on the stock.

Report

12/22

07:18 am

cytk

Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..

Low Report

Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..

Report

12/22

07:03 am

cytk

Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Low Report

Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Report

12/22

06:01 am

cytk

Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Barclays PLC.

Medium Report

Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Barclays PLC.

Report

12/21

04:58 pm

cytk

Cytokinetics set to battle Bristol Myers as FDA approves heart drug [Yahoo! Finance]

Medium Report

Cytokinetics set to battle Bristol Myers as FDA approves heart drug [Yahoo! Finance]

Report

12/20

09:38 am

cytk

Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)? [Yahoo! Finance]

Medium Report

Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)? [Yahoo! Finance]

Report

12/19

07:08 pm

cytk

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms [Yahoo! Finance]

Medium Report

Report

12/19

04:00 pm

cytk

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Medium Report

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Report

12/19

11:24 am

cytk

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? [Yahoo! Finance]

Low Report

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? [Yahoo! Finance]

Report

12/19

08:27 am

cytk

Low Report

Report

12/18

08:02 am

cytk

Cytokinetics (NASDAQ:CYTK) was given a new $95.00 price target on by analysts at The Goldman Sachs Group, Inc..

Low Report

Cytokinetics (NASDAQ:CYTK) was given a new $95.00 price target on by analysts at The Goldman Sachs Group, Inc..

Report

12/18

07:11 am

cytk

Cytokinetics (NASDAQ:CYTK) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.

Low Report

Cytokinetics (NASDAQ:CYTK) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.

Report

12/17

07:30 am

cytk

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Medium Report

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Report

12/16

04:00 pm

cytk

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Medium Report

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Report

12/16

08:40 am

cytk

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf

Low Report

Report

12/12

02:37 pm

cytk

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Low Report

Report

12/12

08:42 am

cytk

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Medium Report

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.